Intervacc AB (publ) (OM: IVACC)
Health Care · Biotechnology · SE
Skr0.82
-7.44% today · -22.5% 1Y
Intervacc AB (publ) (OM: IVACC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $28.25M and employs 16 people.
Over the last twelve months the share price has lost 22.5%, trading between 0.57 and 1.46.
Tweenvest scores Intervacc AB (publ) across four factors: quality 40/100, value 36/100, growth 100/100. Its strongest factor is growth.
IVACC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $28.25M
- Revenue (TTM)
- $1.87M
- P/E
- —
- EPS
- -0.27
- Dividend yield
- —
- Beta (5Y)
- 0.13
- 52-week high
- Skr1.46
- 52-week low
- Skr0.57
- Avg volume (3M)
- —
- Shares outstanding
- 340.81M
- Employees
- 16
- Next earnings
- —
About Intervacc AB (publ)
Intervacc AB (publ) is a Swedish biotechnology company primarily engaged in the research and development of innovative vaccines designed to combat bacterial infections in animal health. The firm's vaccine pipeline targets various animals, including horses, piglets, and dairy cows, with its key product, Strangvac, specifically developed to prevent equine strangles. Beyond its current offerings, Intervacc is also advancing vaccines against Streptococcus suis and Staphylococcus aureus infections. In addition to vaccine development, the company distributes veterinary medicines and provides essential diagnostic services in veterinary bacteriology to clinics and stud farms. Headquartered in Hägersten, Sweden, Intervacc serves customers across the Nordic countries and the Baltic states.
- ISIN
- SE0009607252
- Founded
- 1983
- Listed since
- Apr 7, 2017
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| CEL-SCI CorporationNYSEAM: CVM | $28.85M | $1.64 | +1.86% |
| TransCode Therapeutics, Inc.NasdaqCM: RNAZ | $28.78M | $1.70 | -8.60% |
| Amplia Therapeutics LimitedASX: ATX | $28.57M | AU$0.08 | -23.81% |
| NextCure, Inc.NasdaqGS: NXTC | $28.56M | $6.24 | -13.09% |
| Matricelf LtdTASE: MTLF | $27.79M | ₪2.60 | +4.20% |
| Zenotech Laboratories LimitedBSE: 532039 | $27.69M | Rs43.06 | -0.02% |
| Kohjin Bio Co., Ltd.TSE: 177A | $27.45M | ¥848.00 | +4.05% |
| Chordia Therapeutics Inc.TSE: 190A | $27.40M | ¥56.00 | -1.75% |
Figures last refreshed Oct 18, 2026.